Welcome to our dedicated page for Roivant Sciences news (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Roivant Sciences Ltd. (Nasdaq: ROIV) generates a steady flow of news as a biopharmaceutical company focused on developing and commercializing medicines for autoimmune, inflammatory and cardiopulmonary diseases. Company updates frequently center on its late-stage clinical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as developments at its subsidiaries Priovant Therapeutics, Immunovant, Pulmovant and Genevant.
Investors following ROIV news can expect detailed coverage of clinical milestones, such as Phase 3 and Phase 2 trial readouts, proof-of-concept data and regulatory filing plans. Recent communications have highlighted positive Phase 3 VALOR results for brepocitinib in dermatomyositis, rapid enrollment in non-infectious uveitis and cutaneous sarcoidosis studies, and six-month off-treatment remission data in Graves’ disease from Immunovant’s batoclimab program. Roivant also issues news about potentially registrational trials for IMVT-1402 across several autoimmune indications and ongoing development of mosliciguat in pulmonary hypertension associated with interstitial lung disease.
Roivant’s news flow also includes quarterly and annual financial results, updates on research and development and general and administrative expenses, and information on capital allocation decisions such as common share repurchase programs. In addition, Genevant-related news may cover progress in lipid nanoparticle intellectual property litigation involving companies such as Moderna and Pfizer/BioNTech, as described in Roivant’s public updates.
This ROIV news page brings together press releases, clinical updates, financial disclosures and other company communications in one place. Readers can use it to monitor trial timelines, regulatory plans, subsidiary activities and financial reporting that Roivant discloses through its press releases and SEC filings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Lokavant, a clinical trial intelligence platform, has announced strategic new hires to bolster its leadership team, appointing AJ Mills as executive vice president of sales, Doug Weatherhead as vice president of marketing, and Meredith Dees as vice president of product. Each brings extensive industry experience spanning over a decade. Mills previously held leadership roles at Clario and ICON, Weatherhead has a background in decentralized clinical trial technology, and Dees has worked in various capacities within clinical research. Lokavant aims to enhance its platform capabilities, accelerating clinical trials and improving patient outcomes.
Lokavant, the clinical trial intelligence platform, has reached significant milestones following a $21 million Series A funding round. Within three months, it has expanded its customer base threefold and increased employee growth by 53%. The platform improves clinical trial efficiency by integrating over 2,000 trials’ data, resulting in a 70x improvement in enrollment forecast accuracy, saving over $1 million per trial. Notably, Lokavant is now a standalone entity under org value="NASDAQ-NMS:ROIV"Roivant Sciences and has made key leadership hires to support its rapid growth.
BOSTON, March 28, 2023 — Covant Therapeutics has announced an exclusive research collaboration with Boehringer Ingelheim focusing on its ADAR1 program to develop a small molecule immunotherapy for cancer patients. Covant's platform accelerates drug discovery for challenging targets like ADAR1. The partnership aims to create an ADAR1 inhibitor to enhance the efficacy of existing immunotherapies. Covant will receive an upfront payment of $10 million and has the potential to earn up to $471 million in milestones along with royalties on global sales. This collaboration highlights ADAR1’s potential to improve cancer treatments and reflects confidence in Covant's innovative approach.
Dermavant Sciences, a Roivant Sciences company, announced positive results from the ADORING 2 Phase 3 trial evaluating VTAMA cream for atopic dermatitis. The study demonstrated that 46.4% of subjects using VTAMA achieved the primary endpoint of clear or almost clear skin, significantly outperforming the vehicle group (18.0%, P<0.0001). Key secondary endpoints were also met, including a 59.1% improvement in EASI scores. The trial showed a rollover rate of 92.4% into a long-term safety study, indicating strong patient retention. VTAMA is already approved for plaque psoriasis, providing a potential advantage in treatment regimens for both children and adults.
Roivant Sciences (Nasdaq: ROIV) announced an investor call on March 15, 2023, to discuss topline results from its ADORING 2 study, a Phase 3 clinical trial for atopic dermatitis. This study is one of two replicate trials designed to evaluate the effectiveness of a potential treatment. The call will be accessible via a registration link provided in the announcement, with a webcast available later on the investor section of Roivant's website. The company is focused on enhancing healthcare delivery and developing transformative medicines through innovative approaches.